STOCK TITAN

[Form 3] Denali Capital Acquisition Corp. Initial Statement of Beneficial Ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3

Denali Capital Acquisition Corp. (SMNR) Form 3 reports initial beneficial ownership by Scilex-related entities following a business combination that closed under an amended merger agreement. Scilex, Inc. indirectly holds 193,750,000 shares of Denali Common Stock, Scilex Bio, Inc. holds 6,250,000 shares, and Scilex Holding Company directly holds 1,054,849 shares. The largest block reflects an exchange of Old Semnur shares into Denali Common Stock at an exchange ratio of 1.25 to 1. The filing documents share origins: exchanges from Series A Preferred, a pre-combination purchase, and conversion of a promissory note.

Denali Capital Acquisition Corp. (SMNR) Form 3 riporta la proprietà beneficiaria iniziale da parte di entità legate a Scilex, a seguito di una fusione contrattualizzata che si è chiusa secondo un accordo di fusione modificato. Scilex, Inc. detiene indirettamente 193.750.000 azioni delle Denali Common Stock, Scilex Bio, Inc. detiene 6.250.000 azioni, e Scilex Holding Company detiene direttamente 1.054.849 azioni. Il maggiore blocco riflette uno scambio di azioni Old Semnur in Denali Common Stock a un rapporto di scambio di 1,25 a 1. Gli documenti della presentazione descrivono l'origine delle azioni: scambi da Series A Preferred, un'acquisizione pre-fusione e la conversione di una nota promissoria.
Denali Capital Acquisition Corp. (SMNR) Form 3 informa la propiedad beneficiaria iniziale da parte de entidades relacionadas con Scilex, tras una operación de negocio que se cerró de acuerdo con un convenio de fusión modificado. Scilex, Inc. detenta indirectamente 193.750.000 acciones de Denali Common Stock, Scilex Bio, Inc. 6.250.000 acciones y Scilex Holding Company 1.054.849 acciones directamente. El bloque más grande refleja un intercambio de acciones Old Semnur por Denali Common Stock a una razón de intercambio de 1,25 a 1. El expediente documenta el origen de las acciones: intercambios de Series A Preferred, una compra pre-fusión y la conversión de una promissory note.
Denali Capital Acquisition Corp. (SMNR) Form 3은 개정된 합병 계약에 따라 마감된 사업결합 이후 Scilex 관련 법인들의 최초의 유익한 소유를 보고합니다. Scilex, Inc.는 Denali Common Stock 193,750,000주를 간접 보유하고, Scilex Bio, Inc.는 6,250,000주, Scilex Holding Company는 직접 1,054,849주를 보유합니다. 가장 큰 블록은 Old Semnur 주를 Denali Common Stock으로 1.25 대 1의 교환비로 교환한 것을 반영합니다. 제출 서류는 주식의 기원: Series A Preferred의 교환, 합병 전 매입, 그리고 약속어음의 전환을 문서화합니다.
Denali Capital Acquisition Corp. (SMNR) Form 3 signale la propriété bénéficiaire initiale par des entités liées à Scilex à la suite d'une opération de fusion qui s'est clôturée conformément à un accord de fusion modifié. Scilex, Inc. détient indirectement 193 750 000 actions de Denali Common Stock, Scilex Bio, Inc. détient 6 250 000 actions, et Scilex Holding Company détient directement 1 054 849 actions. Le plus gros bloc reflète un échange d'anciennes actions Semnur contre Denali Common Stock à un ratio d'échange de 1,25 pour 1. Le dossier indique l'origine des actions : échanges issus de Series A Preferred, un achat pré-fusion et la conversion d'une promissory note.
Denali Capital Acquisition Corp. (SMNR) Form 3 meldet die anfängliche wirtschaftlich berechtigte Eigentümerschaft durch Scilex-bezogene Einheiten nach einer Transaktion, die unter einem geänderten Fusionsvertrag abgeschlossen wurde. Scilex, Inc. hält indirekt 193.750.000 Aktien von Denali Common Stock, Scilex Bio, Inc. hält 6.250.000 Aktien, und Scilex Holding Company hält direkt 1.054.849 Aktien. Der größte Block spiegelt einen Austausch alter Semnur-Aktien in Denali Common Stock im Austauschverhältnis von 1,25 zu 1 wider. Die Einreichung dokumentiert die Herkunft der Aktien: Austausche aus Series A Preferred, ein Vorfusionserwerb und die Umwandlung einer Schuldschein.
Denali Capital Acquisition Corp. (SMNR) يقدِم نموذج Form 3 ملكية مستفيدة ابتدائية من قبل جهات مرتبطة بـ Scilex عقب عملية دمج أغلقت وفق اتفاق دمج معدّل. Scilex, Inc. تملك بشكل غير مباشر 193,750,000 سهم من Denali Common Stock، وتملك Scilex Bio, Inc. 6,250,000 سهم، وتملك Scilex Holding Company بشكل مباشر 1,054,849 سهم. أكبر كتلة تعكس تبادل أسهم Old Semnur إلى Denali Common Stock بمعدل تبادل 1.25 إلى 1. توثق الوثائق المقدّمة أصول الأسهم: تبادلات من Series A Preferred، وشراء قبل الدمج، وتحويل سند وعد.
Denali Capital Acquisition Corp. (SMNR) 的 Form 3 报告了在经过经修订的并购协议完成的商业合并后,Scilex 相关实体的初始受益所有权。Scilex, Inc. 间接持有 Denali Common Stock 的 193,750,000 股,Scilex Bio, Inc. 持有 6,250,000 股,Scilex Holding Company 直接持有 1,054,849 股。最大的一块反映了以 1.25 比 1 的换股比率将 Old Semnur 股票换成 Denali Common Stock。申报文件记录了股票来源:来自 Series A Preferred 的换股、并购前购买以及债务票据的转股。
Positive
  • Clear disclosure of share origins including the business combination exchange ratio of 1.25 to 1
  • Substantial ownership by Scilex entities (193,750,000; 6,250,000; and 1,054,849 shares) is explicitly documented
Negative
  • None.

Insights

TL;DR: Scilex entities now hold a substantial combined stake through the business combination, which materially concentrates ownership.

The Form 3 discloses that Scilex, Inc. indirectly controls 193.75 million shares and related entities control additional shares, creating a significant ownership position post-merger. The 1.25-to-1 exchange ratio explains the mechanics of the share conversion from Old Semnur into the Issuer. For investors, concentrated ownership can influence governance, strategic direction, and liquidity; the specifics here are clearly documented and allow modeling of potential voting power and dilution effects.

TL;DR: Large insider holdings and the described share exchanges are material for board control and corporate actions.

The filing shows Scilex Holding Company and its subsidiaries reporting director status and multi-hundred-million share positions originating from the business combination and related transactions (Series A Preferred exchange, prior purchase, and note conversion). This concentration is material to governance assessments because it affects control dynamics and the potential for related-party influence. The disclosure is straightforward and sufficient to evaluate ownership provenance but does not include downstream voting agreements or lock-ups.

Denali Capital Acquisition Corp. (SMNR) Form 3 riporta la proprietà beneficiaria iniziale da parte di entità legate a Scilex, a seguito di una fusione contrattualizzata che si è chiusa secondo un accordo di fusione modificato. Scilex, Inc. detiene indirettamente 193.750.000 azioni delle Denali Common Stock, Scilex Bio, Inc. detiene 6.250.000 azioni, e Scilex Holding Company detiene direttamente 1.054.849 azioni. Il maggiore blocco riflette uno scambio di azioni Old Semnur in Denali Common Stock a un rapporto di scambio di 1,25 a 1. Gli documenti della presentazione descrivono l'origine delle azioni: scambi da Series A Preferred, un'acquisizione pre-fusione e la conversione di una nota promissoria.
Denali Capital Acquisition Corp. (SMNR) Form 3 informa la propiedad beneficiaria iniziale da parte de entidades relacionadas con Scilex, tras una operación de negocio que se cerró de acuerdo con un convenio de fusión modificado. Scilex, Inc. detenta indirectamente 193.750.000 acciones de Denali Common Stock, Scilex Bio, Inc. 6.250.000 acciones y Scilex Holding Company 1.054.849 acciones directamente. El bloque más grande refleja un intercambio de acciones Old Semnur por Denali Common Stock a una razón de intercambio de 1,25 a 1. El expediente documenta el origen de las acciones: intercambios de Series A Preferred, una compra pre-fusión y la conversión de una promissory note.
Denali Capital Acquisition Corp. (SMNR) Form 3은 개정된 합병 계약에 따라 마감된 사업결합 이후 Scilex 관련 법인들의 최초의 유익한 소유를 보고합니다. Scilex, Inc.는 Denali Common Stock 193,750,000주를 간접 보유하고, Scilex Bio, Inc.는 6,250,000주, Scilex Holding Company는 직접 1,054,849주를 보유합니다. 가장 큰 블록은 Old Semnur 주를 Denali Common Stock으로 1.25 대 1의 교환비로 교환한 것을 반영합니다. 제출 서류는 주식의 기원: Series A Preferred의 교환, 합병 전 매입, 그리고 약속어음의 전환을 문서화합니다.
Denali Capital Acquisition Corp. (SMNR) Form 3 signale la propriété bénéficiaire initiale par des entités liées à Scilex à la suite d'une opération de fusion qui s'est clôturée conformément à un accord de fusion modifié. Scilex, Inc. détient indirectement 193 750 000 actions de Denali Common Stock, Scilex Bio, Inc. détient 6 250 000 actions, et Scilex Holding Company détient directement 1 054 849 actions. Le plus gros bloc reflète un échange d'anciennes actions Semnur contre Denali Common Stock à un ratio d'échange de 1,25 pour 1. Le dossier indique l'origine des actions : échanges issus de Series A Preferred, un achat pré-fusion et la conversion d'une promissory note.
Denali Capital Acquisition Corp. (SMNR) Form 3 meldet die anfängliche wirtschaftlich berechtigte Eigentümerschaft durch Scilex-bezogene Einheiten nach einer Transaktion, die unter einem geänderten Fusionsvertrag abgeschlossen wurde. Scilex, Inc. hält indirekt 193.750.000 Aktien von Denali Common Stock, Scilex Bio, Inc. hält 6.250.000 Aktien, und Scilex Holding Company hält direkt 1.054.849 Aktien. Der größte Block spiegelt einen Austausch alter Semnur-Aktien in Denali Common Stock im Austauschverhältnis von 1,25 zu 1 wider. Die Einreichung dokumentiert die Herkunft der Aktien: Austausche aus Series A Preferred, ein Vorfusionserwerb und die Umwandlung einer Schuldschein.
SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Scilex Holding Co

(Last) (First) (Middle)
960 SAN ANTONIO RD

(Street)
PALO ALTO CA 94303

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
09/22/2025
3. Issuer Name and Ticker or Trading Symbol
Denali Capital Acquisition Corp. [ SMNR ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 193,750,000(1) I(2) By Scilex, Inc.
Common Stock 6,250,000 I(3) By Scilex Bio, Inc.
Common Stock 1,054,849 D(4)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
Scilex Holding Co

(Last) (First) (Middle)
960 SAN ANTONIO RD

(Street)
PALO ALTO CA 94303

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Scilex, Inc.

(Last) (First) (Middle)
960 SAN ANTONIO RD

(Street)
PALO ALTO CA 94303

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. Represents shares of the Common Stock of the Issuer (f/k/a Denali Capital Acquisition Corp. ("Denali")) received pursuant to a business combination (the "Business Combination") which was effectuated in accordance with the terms of the Agreement and Plan of Merger, dated as of August 30, 2024 (as amended on April 16, 2025 and July 22, 2025), by and among the Issuer, Denali Merger Sub, Inc., a wholly owned subsidiary of the Issuer, and the company formerly known as Semnur Pharmaceuticals, Inc. ("Old Semnur"). Upon consummation of the Business Combination, the reporting entities' shares of the common stock of Old Semnur were exchanged for the shares of Common Stock of the Issuer reported in this row, based on an exchange ratio of 1.25 to 1.
2. Scilex, Inc. is the direct owner of the 193,750,000 shares of the Issuer's Common Stock set forth in this row. Scilex, Inc. is a subsidiary of Scilex Holding Company.
3. Scilex Bio, Inc. is the direct owner of 6,250,000 shares set forth in this row. Scilex Bio, Inc. is a majority-owned subsidiary of Scilex Holding Company.
4. Comprised of: (i) 542,361 shares of Common Stock issued pursuant to the Business Combination upon the exchange of 5,423,606 shares of Series A Preferred Stock of Old Semnur (each share of Series A Preferred Stock of Old Semnur was exchanged for one share of Series A Preferred Stock of the Issuer and 1/10th of a share of Common Stock of the Issuer), (ii) 500,000 shares of Common Stock purchased by Scilex Holding Company prior to the Business Combination, and (iii) 12,488 shares of Common Stock issued upon conversion of the Convertible Promissory Note previously issued by Denali Capital Acquisition Corp. to Scilex Holding Company, which was converted upon consummation of the Business Combination.
/s/ Henry Ji, Scilex Holding Company, Chief Executive Officer and President 09/23/2025
/s/ Henry Ji, Scilex, Inc., Chief Executive Officer and President 09/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 3 for Denali Capital Acquisition Corp. (DNQWF)?

The Form 3 was filed on behalf of Scilex Holding Company, Scilex, Inc., and Scilex Bio, Inc., with signatures by Henry Ji as CEO and President.

How many Denali shares does Scilex, Inc. indirectly own according to the filing?

Scilex, Inc. is reported as the direct owner of 193,750,000 shares of Denali Common Stock.

What transaction produced the large block of shares reported on the Form 3?

The shares resulted from a business combination effectuated under an Agreement and Plan of Merger, with Old Semnur shares exchanged into Denali Common Stock.

What is the exchange ratio used to convert Old Semnur shares into Denali Common Stock?

The filing states an exchange ratio of 1.25 to 1 for Old Semnur shares into the Issuer's Common Stock.

What components make up the 1,054,849 shares reported as directly owned?

They consist of (i) 542,361 shares from Series A Preferred exchange, (ii) 500,000 shares purchased pre-combination, and (iii) 12,488 shares from conversion of a promissory note.
DNQWF

:DNQWF

DNQWF Rankings

DNQWF Latest SEC Filings

DNQWF Stock Data